This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.48% per year. These returns cover a period from January 1, 1988 through May 5, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.
NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Eldorado Gold Corporation (EGO) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
EGOPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up
by Zacks Equity Research
NVS' first-quarter earnings and sales beat estimates. Based on the strong momentum of its key drugs, the company raises its annual guidance. Share price rises.
NVSPositive Net Change RHHBYPositive Net Change PFEPositive Net Change BAYRYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
StoneCo Ltd. (STNE)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
STNENegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
BMY Falls 4% Post Q1 Earnings: Should You Buy, Sell or Hold the Stock?
by Ekta Bagri
Bristol Myers' first-quarter performance and raised annual guidance are encouraging. However, we recommend investors to stay on the sidelines as generic competition for legacy drugs and recent pipeline setbacks weigh on the stock.
BMYNegative Net Change PFEPositive Net Change MRKNegative Net Change
biotechnology biotechs earnings-report medical pharmaceuticals
Zoetis Gears Up to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS' higher companion animal product sales are likely to have driven revenues in first-quarter 2025 in both the United States and International segments.
NVAXNegative Net Change ZTSPositive Net Change CTMXPositive Net Change ARGXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Exelixis' Q1 Earnings: Will Cabometyx Maintain Momentum?
by Zacks Equity Research
Investors will likely focus on the demand for Cabometyx and pipeline updates when EXEL reports Q1 results.
AZNPositive Net Change VRTXPositive Net Change EXELNegative Net Change ARGXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Recursion Pharmaceuticals to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter 2025 earnings release, given the absence of a marketed product.
NVAXNegative Net Change CTMXPositive Net Change ARGXPositive Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline
by Zacks Equity Research
Gilead Sciences' Q1 earnings and sales miss estimates on lower oncology drug sales. The stock is trading down.
GSKNegative Net Change GILDPositive Net Change ANIPPositive Net Change ADMAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
CytomX Gears Up to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
On the Q1 2025 earnings call, investors can expect updates regarding the progress in the development of CTMX's lead candidate, CX-2051, for colorectal cancer.
AMGNNegative Net Change NVAXNegative Net Change CTMXPositive Net Change ARGXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook
by Zacks Equity Research
BMY beats on both earnings and sales in the first quarter of 2025. The company raises its guidance for the full year.
BMYNegative Net Change PFEPositive Net Change ANIPPositive Net Change ADMAPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?
by Ahan Chakraborty
Despite the current downward trend, long-term investors may stay invested in NVO stock due to strong demand for its GLP-1 drugs.
NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Regulus (RGLS) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
RGLSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Biotech Stock Roundup: BMY Down on Study Data, Updates From REGN & More
by Ekta Bagri
BMY and REGN are in the spotlight this week following study data and regulatory updates, respectively.
REGNNegative Net Change SNYNegative Net Change BMYNegative Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Buy 5 High ROE Stocks as Markets Break Tariff-Induced Losing Streak
by Supriyo Bose
CBOE, AGNC, JAZZ, AES and CNSWF are some of the stocks with high ROE to profit from as markets expect the tariff war to end soon.
AGNCPositive Net Change AESPositive Net Change CBOEPositive Net Change JAZZPositive Net Change CNSWFNegative Net Change
biofuels biotechnology fin-tech finance reit tech-stocks
Implied Volatility Surging for BioMarin Stock Options
by Zacks Equity Research
Investors need to pay close attention to BMRN stock based on the movements in the options market lately.
BMRNNegative Net Change
biotechnology biotechs medical
Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know
by Zacks Equity Research
INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
NVSPositive Net Change INCYNegative Net Change CTMXPositive Net Change ARGXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
5 Stocks With Recent Price Strength Amid Tariff-Led Volatility
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are HRTG, MRX, KINS, ANIP, HCI.
MRXPositive Net Change HCIPositive Net Change ANIPPositive Net Change HRTGPositive Net Change KINSPositive Net Change
biotechnology finance insurance
Regeneron to Report Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports first-quarter results on April 29.
REGNNegative Net Change AZNPositive Net Change GILDPositive Net Change VRTXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?
by Ahan Chakraborty
Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.
SNYNegative Net Change BMYNegative Net Change MRKNegative Net Change GILDPositive Net Change ABBVPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novartis to Report Q1 Earnings: Will Key Drugs Maintain Momentum?
by Zacks Equity Research
NVS' first-quarter performance has likely benefited from strong growth in Kisqali, Kesimpta, Pluvicto, Leqvio, Scemblix and Fabhalta.
AZNPositive Net Change NVSPositive Net Change GILDPositive Net Change VRTXPositive Net Change
biotechnology medical pharmaceuticals
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study
by Zacks Equity Research
Eli Lilly's stock surges as its investigational oral GLP-1 pill, orforglipron, achieves the primary and key secondary goals in the first late-stage study for adults with T2D.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?
by Ekta Bagri
Bristol Myers is looking to turn its business around, banking on the strong uptake of new drugs. However, the 2025 outlook is not bright and we recommend investors to wait and watch for now.
BMYNegative Net Change PFEPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?
by Ekta Bagri
Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be a significant boost. We recommend investors to wait and watch for now.
GSKNegative Net Change MRKNegative Net Change GILDPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Top Beauty and Cosmetics Stocks to Boost Your Portfolio
by Ansuiya Mohta
Leading beauty and cosmetics stocks like EL, COTY and ULTA are thriving on innovation, technological advancements and sustainability.
ELNegative Net Change ULTANegative Net Change NUSNegative Net Change COTYNegative Net Change ELFPositive Net Change
artificial-intelligence biotechnology consumer-staples e-commerce